

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



AQ

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 9/51</b>		A1	(11) International Publication Number: <b>WO 96/29998</b> (43) International Publication Date: 3 October 1996 (03.10.96)
(21) International Application Number: <b>PCT/EP96/01354</b>		(81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 26 March 1996 (26.03.96)		(30) Priority Data: PD95A000065 28 March 1995 (28.03.95) IT PD96A000021 5 February 1996 (05.02.96) IT	
(71) Applicant (for all designated States except US): FIDIA ADVANCED BIOPOLYMERS S.R.L. [IT/IT]; Via de' Carpenteri, 3, I-72100 Brindisi (IT).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventors; and			
(73) Inventors/Applicants (for US only): PALLADO, Paolo [IT/IT]; Via Ravel, 8, I-35132 Padova (IT). BENEDETTI, Luca [IT/IT]; Via Durando, 26, I-36100 Vicenza (IT). CALLEGARO, Lanfranco [IT/IT]; Via Monte Grappa, 6, I-36016 Thiene (IT).			
(74) Agent: GERVASI, Gemma; Notarbartolo & Gervasi S.r.l., Viale Bianca Maria, 33, I-20122 Milan (IT).			
(54) Title: NANOSPHERES COMPRISING A BIOCOMPATIBLE POLYSACCHARIDE			
(57) Abstract			
<p>Microspheres, having a size lower than 1 <math>\mu</math> and comprising a biocompatible polysaccharidic polymer, are prepared with a process comprising the precipitation of polymer induced by means of a supercritical antisolvent (SAS). These microspheres are used as vehicling agents or carriers in the preparation of pharmaceutical compositions administrable by oral, nasal, pulmonary, vaginal or rectal route. These microspheres can also be advantageously used as vehicling agent or carriers in the preparation of pharmaceutical compositions for the treatment of human diseases associated with genetic defects, for the preparation of diagnostics and in the agro-alimentary industry.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Libera	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

## NANOSPHERES COMPRISING A BIOCOMPATIBLE POLYSACCHARIDE

### FIELD OF THE INVENTION

5    The present invention relates to:

- microspheres having a diameter  $\geq 0.1$  and  $< 1 \mu$ , comprising a biocompatible polysaccharide polymer and optionally at least one active ingredient,
- pharmaceutical compositions containing said microspheres

10    administrable by oral, nasal, pulmonary, vaginal or rectal route,

- the use of microspheres having a diameter ranging from 0.1 to 1  $\mu$  as carriers for the preparation of pharmaceutical compositions for human genic therapy, for the preparation of diagnostics and in the agroalimentary industry.

15    - a process for the preparation of microspheres having a dimension of between 0,1 and 1  $\mu$  comprising the precipitation of said polymer induced by means of a supercritical antisolvent (SAS).

### TECHNOLOGICAL BACKGROUND

Major advances have recently been made in pharmaceutical technology to

20    research new methods for the preservation of the intrinsic activity of polypeptides and to render them absorbent. Formulations able to ensure a reproducible absorption of these active molecules have the advantage of lacking side effects, unlike synthetic polymers. Of all the most widely used natural polymers, the category of acidic polysaccharides

25    is of particular interest. One of these, hyaluronic acid, a

- 2 -

polysaccharide widely distributed throughout animal organisms. is constituted by units of D-glucuronic acid and N-acetyl D-glucosamine in alternate order. Its molecular weight can vary according to the methods used for its extraction and/or purification (EP 0138572 reg. 5 on 25.7.90; EPA 0535200 published on 7.4.93; PCT Application No. WO 95/04132 published on 9.2.95; PCT Patent Application No. WO 95/24497 published on 14.9.95).

Besides the polymer's chemical-physical properties, the release methods and systems for biologically active molecules are also 10 particularly important, such as microspheres which seem to be among the most versatile release systems. EPA 0517565 discloses a process for the preparation of microspheres, whose dimensions range between 1- 15 100 µm, wherein the polysaccharide ester dissolved in an aprotic solvent such as DMSO, is added to a mixture of a high-viscosity mineral oil containing a non ionic surface active agent and ethyl acetate, which is a solvent for DMSO and the mineral oil, but not for the polysaccharide ester, which therefore precipitates in the form of 20 microspheres having therefore the above mentioned dimensions.

Today, various techniques are known which involve the use of 25 supercritical fluids for the production of finely subdivided particles with a narrow granulometric distribution curve. The supercritical antisolvent process is generally performed at moderate temperatures and enables the solvent to be completely removed from the precipitation environment. The applications concern substances that are heat-sensitive or difficult to handle, such as explosives (Gallagher, P. M. et al., 1989, *Supercritical Fluid Science and Technology* - Am. Chem. Soc. 334-354). Other applications concern the

- 3 -

production of polymers in the form of fibers (Dixon, D. J. et al., 1993, *J. Appl. Polym. Sci.* 50, 1929-1942) and in the form of microparticles, including microspheres (Dixon, D. J..et al., 1993, *AICHE J.*, 39, 1, pp 127-139). In the pharmaceutical field, the main interest is in the treatment of proteins (Tom, J. W., et al., 1994, *Supercritical Fluid Engineering Science*, pp 238-257, ACS Symp. Chap. 19, Ed. H. Kiran and J. F. Brennecke; Yeo, S. D.. et al. 1993, *Biotech. and Bioeng.*, 41, pp 341-346) and biodegradable polymers, such as poly(L-lactic acid) (Randolph, T. W.. et al. 1993, *Biotechnol. Prog.*, 9, 429-435; Yeo, S. D., et al. 1993, *Macromolecules*, 26, 6207-6210). Various methods have been devised for precipitation with a supercritical antisolvent. The semi-discontinuous method (Gallagher et al., 1989), involves injection of the antisolvent in the liquid solution which has already been prepared in the desired working conditions. The operation must be performed in a stepwise fashion to ensure that the liquid is removed, the final quantities of product are very limited and the spheres measure far more than 1  $\mu$  in size. Precipitation with a compressed antisolvent (PCA) involves injection of the solution in the high-density supercritical fluid (SCF) (Dixon et al.. 1991; Dixon and Johnston, 1993). The injection times are much reduced to guarantee complete dissolution of the liquid. so the quantity of precipitate is very low, giving microfibers with an ordered structure.

The continuous process (Yeo et al., 1993a) enables the solution and the antisolvent to be injected simultaneously in the precipitation environment; the liquid expands and evaporates in the continuous phase, constituted by the SCF. The solution is injected through a

- 4 -

micrometric nozzle with a diameter ranging between 10 and 30  $\mu$ . Solutions must be diluted to avoid blocking the nozzle and to prevent reticulate structures being formed. Consequently, the quantity of solid solute injected is very low. Moreover, a high ratio between the  
5 volume of antisolvent and solution must be used to continuously remove the liquid solvent from the precipitation vessel.

When the solution is placed in the precipitator and the container is loaded by means of SCF up to the desired pressure, the process assumes a completely discontinuous character (Yeo et al., 1993 a,b). By this  
10 technique, microspheres with a diameter of over 1  $\mu$  have been obtained. All the methods described here are accompanied by a final washing step to prevent the precipitate being resolubilized by the solvent. However, none of the cited techniques has been specifically applied to the production of high-molecular-weight biocompatible  
15 polysaccharide polymers and in particular the HYAFFs, namely the ester of hyaluronic acid, which are obtained by the procedure described in US patent 4,851,521.

#### SUMMARY OF THE INVENTION

The Applicant has unexpectedly found that with the discontinuous SAS  
20 technique it is possible to obtain in quantitative yields microspheres with a diameter of less than 1  $\mu$  comprising a polysaccharide biocompatible polymer.

Object of the present invention are therefore microspheres having a dimension  $\geq 0,1 \mu$  and  $< 1 \mu$  comprising a biocompatible polysaccharide  
25 polymer.

A further object of the present invention are pharmaceutical compositions administrable by oral, nasal, pulmonary, vaginal or

- 5 -

rectal route, containing said microspheres as vehicling agents or carriers in combination with at least one active ingredient and optionally with further conventional excipients.

A further object of the present invention relates to said  
5 microspheres further comprising at least one of the following active principles: a pharmaceutically active polypeptide, a Granulocyte Macrophage Colony Stimulating Factor (GMCSF), a trophic factor, an immunoglobulin, a natural or a synthetic derivative of a ganglioside, an antiviral, an antiasthmatic an antiinflammatory agent, an  
10 antibiotic and an antimycotic agent.

A further object of the present invention relates to pharmaceutical compositions administrable by oral, nasal, pulmonary, vaginal or rectal route containing the microspheres inglobating the above mentioned active principles, optionally in combination with other  
15 conventional excipients.

A further object of the present invention relates to the use of microspheres having a diameter comprised between 0.1 and 1  $\mu$  as carriers in the preparation of diagnostics and in agroalimentary industry. Moreover they can be advantageously used as vehicling agent  
20 or carriers of a gene, for the preparation of pharmaceutical compositions for the treatment of diseases associated with genic defects.

A further object of the present invention resides in the discontinuous process for the preparation of microspheres having a dimension  
25 comprised between 0.1 and 1  $\mu$  and comprising the precipitation of said polymer induced by means of a supercritical antisolvent (SAS).

The process object of the present invention comprises the following

- 6 -

steps:

- a) dissolving the polysaccharide biocompatible polymer in an aprotic solvent at concentrations ranging from 0.1 to 5% by weight.
- b) charging the solution of step (a) in a pressure proof container having at the top and at the base steel filters with an average cut-off lower than 0.1  $\mu$ ;
- c) loading from underneath the antisolvent until reaching the pressure at which said fluid becomes supercritical at a temperature ranging from 25 to 60°C,
- d) removing the aprotic solvent, by flowing said supercritical fluid,
- e) depressurizing the pressure proof container and collecting the precipitated product.

Contrarily to what one could foresee from the above mentioned prior art (teaching that, with the SAS discontinuous technique, process times are longer than with the continuous one, nucleation occurs in the bulk liquid phase where the supercritical antisolvent is dissolved and therefore the formation of large particles with broad granulometric distribution is expected), surprisingly the expanding conditions adopted with the process according to the present invention enable the onset of the nucleation process in a well-expanded media so that the formation of a high number of nucleation centres is achieved. This factor, combined with the amorphous nature of the solid solute, leads to the formation of microspheres whose dimension is comprised in the above mentioned range and moreover with a narrow granulometric distribution curve.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 represents a SEM photograph (Scanning Electron Microscope) of

- 7 -

HYAFF-11 microspheres obtained by following the operating conditions reported in Example 1, starting from a HYAFF concentration in DMSO equal to 1% w/w (bar=1 micron);

Figure 2 is a photograph of the sample relative to Fig. 1 with a 5 higher magnification (bar=1 micron);

Figure 3 represents a SEM photograph of HYAFF-11 p75 microspheres obtained according to the working conditions of Example 2, starting from a HYAFF concentration in DMSO equal to 1% w/w (bar=1 micron);

Figure 4 represents a SEM photograph of HYAFF-7 microspheres prepared 10 by following the operating conditions described in Example 3, starting from a HYAFF concentration in DMSO equal to 1% w/w (bar=1 micron);

Figure 5 represents a SEM photograph of ACP p10 microspheres obtained by following the operating conditions described in Example 4, starting from an ACP concentration in DMSO equal to 1% w/w (bar=1 micron);

15 Figure 6 represents a SEM photograph of ALAFF microspheres, prepared by following the operating conditions described in Example 5 starting from an ALAFF concentration in DMSO equal to 1% w/w (bar= 1 micron).

#### **DETAILED DESCRIPTION OF THE INVENTION**

The biocompatible polysaccharide polymer which is comprised in the 20 microspheres according to the present invention is preferably an ester of a polysaccharide acid such a hyaluronic acid ester, selected from those described in US 4,851,521, which we incorporate by reference, a crosslinked ester of hyaluronic acid selected from those disclosed in EP 0341745 B1 which we incorporate by reference . an 25 ester of chitin selected from those described in PCT W093/06136, which we incorporate by reference , an ester of pectin selected from those mentioned in PCT W093/14129, which we incorporate by reference. an

- 8 -

ester of gellan selected from those disclosed in US 5,332,809, which we incorporate by reference, an ester of alginic acid selected from those reported in USPs 5,264,422 and 5,336,668, which we incorporate by reference. Particularly preferred esters are the  
5 total or partial benzyl ester of hyaluronic acid. Among the partial ester a particularly preferred ester is the benzyl ester with 75% of the carboxy function of hyaluronic acid esterified with benzyl alcohol.

The pharmaceutical compositions according to the present invention  
10 containing said microspheres as vehicling agents or carriers, in combination with at least one active agent can optionally be formulated in a controlled release form, in order to have the desired rate of absorption, with suitable excipients normally used for preparing this type of formulations.

15 Preferred pharmaceutically active polypeptides which can be comprised in the microspheres according to the present invention are calcitonin, insulin, preferred trophic factors, which can be incorporated in the microspheres according to the present invention are the Nerve Growth Factor (h-NGF), the Ciliary Neuronotrophic Growth Factor (h-CNTF).

20 The pharmaceutical compositions containing the above microspheres incorporating the above listed active principles, can optionally be formulated in controlled release form, in order to have the desired rate of absorption, with suitable excipients normally used for preparing this type of formulations.

25 As pointed out above the microspheres having a diameter ranging from 0.1 to 1  $\mu$  can be advantageously used as vehicling agents in the diagnostic sector. In particular, according to the type of technique

- 9 -

to be used for diagnostic analysis, such as NMR, ultrasound, X rays, the microspheres can be loaded with paramagnetic agents such as magnetite, or they may be concave in structure, or, alternatively, they may be loaded with nonionic contrast agents, or, lastly, with 5 radioactive isotopes such as  $\text{TC}^{99m}$ .

As a matter of fact vehicling of the contrast agents by means of microspheres limits interaction with the blood, thus reducing the onset of the side effects typically caused by contrast agents.

As previously pointed out, another important sector in which the 10 microspheres having a diameter comprised between 0.1 and 1  $\mu$  according to the present invention can be advantageously used is the preparation of pharmaceutical compositions for the treatment of diseases associated with genic defects.

Much effort is currently being put into scientific research in this 15 field to find remedies for genetic-type malformations or metabolic diseases of a genetic origin. Most of the work being done is aimed at identifying and preparing vehicling systems for healthy genetic material to be administered to patients suffering from such malformations and diseases. One of the possibilities is represented by 20 the encapsulation of healthy genes in microspheres which are able to penetrate more deeply into the tissues and sustain contact with the cell surfaces to be treated for longer periods of time. It follows that the adherence of the microspheres to the cell surfaces enables 25 the release of genetic material transported to the close vicinity of the target cells. In particular, the microspheres having a diameter ranging from 0.1 to 1  $\mu$  containing the biocompatible polysaccharide polymer according to the present invention represent an ideal

- 10 -

transport system for biological material, and in this particular case for healthy genes, thanks to their very small dimensions and specific mucoadhesiveness. Among the possible applications for said microspheres in the treatment of human diseases associated with genic 5 defects a preferred one is in their use as vehicling agents of single genes which encode specific enzymes, for the treatment of diseases caused by a deficit of the same enzymes. There are in fact numerous diseases which derive from an enzyme deficit or hyperactivity, which is caused by defects occurred in the specific gene encoding this 10 enzyme.

For example diseases of this type are:

- phenylketonuria, due to a deficit of phenylalanine hydroxylase.
- alkaptonuria, due to a deficit of homogentisic acid oxidase.
- albinism due to a deficit of tyrosinase and many other diseases 15 involving amino acid metabolism;
- diseases involving glycogen accumulation, some of which are fatal at birth, due to deficit of enzymes such as glucose-6-phosphatase, brancher or de-brancher enzymes, and  $\alpha$ -lysosomal glucosidase enzymes:
- 20 - carbohydrate metabolism disorders
- Wilson's disease, involving a defect in ceruloplasma, the protein which transports copper
- porphyria caused by a deficit in porphobilinogen deaminase, uroporphyrinogen oxydase, protoporphyrinogen oxydase
- 25 - coproporphyrinogen oxydase,
- gout due to hypoxanthine-guanine-phosphoribosyl transferase deficiency, or hyperactivity of  $\beta$ -phosphoribosyl-1-pyrophosphate

- 11 -

transferase.

- diseases involving lysosomal accumulation such as gangliosidosis. due to  $\beta$ -galactosidase deficiency, leukodystrophy, Niemann-Pick's disease due to sphingomyelinase deficiency, Gaucher's disease due to glucosyl-ceramidase deficiency, Fabry's disease, due to  $\alpha$ -galactosidase deficiency, mucopolysaccharidoses etc..
- connective tissue disorders (brittle bone syndrome, Ehlers-Danlos syndrome, Marfan syndrome),

10 Besides their use in enzymatic deficits, the microspheres can be used to vehicle single genes in any pathologies wherein such genes are altered, such as malformative diseases of genetic origin (Down's syndrome, arachnodactyly etc.), hereditary diseases such as:

- hemoglobinopathies (sickle-cell anaemia, thalassaemia etc.).
- 5 - cystic fibrosis.
- primitive hyperlipoproteinemia and other lipid metabolism disorders, wherein single or multifactorial gene disorders with hereditary transmission and complex modalities of different genes, interact with environmental factors, thus determining hyperlipoproteinemia having a different degree of seriousness in different members of the same family.
- cancer wherein it has been ascertained that genetic alterations exist at the level of the differentiation and of the failed control of cellular growth.

15 Finally as pointed out above, the microspheres having a diameter of from 0.1 to 1  $\mu$  can be advantageously used in the agro-alimentary

- 12 -

sector, for example as a vehicle for plant treatments or for the preservation of additives.

The preferred supercritical fluid used as antisolvent in the process according to the present invention is selected from carbon dioxide 5 ( $\text{CO}_2$ ) and hydrofluorocarbons, such as trifluoromethane.

In this specific case when  $\text{CO}_2$  in step (c) it is charged with a loading rate or pressure gradient ranging from 3 to 20 bar/min, preferably 10 bar/min, until a pressure is reached in the pressure proof container ranging from 80 to 120 bar/min, more preferably 100 10 bar/min.

Precipitation of the polymer in this step is induced by the supercritical antisolvent which, by solubilizing and expanding the solution, causes a decrease in the solvent power of the liquid and simultaneous evaporation. The dissolved product, not soluble in the 15 SCF, separates as a solid.

The particles in step (d) are washed with the antisolvent to remove the liquid completely before the precipitator is depressurized.

The depressurization in step (e) of the process according to the present invention is preferably carried out by using a pressure 20 gradient of 5 bar/min.

The preferred solvent used in step (a) to dissolve the biocompatible polysaccharide polymer is selected from dimethylsulfoxide and N-methylpyrrolidone.

The microspheres according to the present invention further comprising 25 at least one of the above mentioned active principles can be prepared in two alternative ways.

The first one encompasses the addition of the active principle in step

- 13 -

(a) of the process according to the present invention, after the dissolution of the biocompatible polysaccharide polymer in the aprotic solvent.

The coprecipitation of the active principle in step (c) with the  
5 biocompatible polysaccharide polymer does not alter the form or morphology of the precipitate.

According to the latter way, the microspheres coming from step (e),  
are suspended in a buffered solution preferably a phosphate buffer  
solution containing the desired active principle at a suitable  
10 concentration in order to obtain the desired active ingredient  
titer/mg of microsphere, and the suspension is subjected to  
liophylization at the liquid nitrogen temperature.

We report hereafter, for purely illustrative purposes, some examples  
of how to obtain microspheres made with polymer alone or with polymer  
15 containing pharmacologically active substances. Any variations which  
would be obvious to an expert in the field are to be considered as  
coming within the scope of the present invention.

Example 1: Preparation of microspheres wherein the starting polymer is  
HYAFF-11 (benzyl ester of hyaluronic acid)

20 A hyaluronic acid ester, wherein all the carboxy groups of hyaluronic  
acid are esterified with benzyl alcohol, is dissolved in an aprotic  
solvent, such as dimethylsulfoxide (DMSO), at a concentration varying  
between 0.1 and 5% in weight, generally 1% w/w. Once the polymer has  
solubilized, the solution is poured into a pressure-proof container  
25 (precipitator), thermostatically controlled with a heated ethylene  
glycol jacket. Porous steel filters with an average cut-off of less  
than 0.1  $\mu$  are screwed onto the base and top of the precipitator.

The liquid is unable to seep through by gravity alone.

Once the container is closed, it is loaded from underneath with hyperpure carbon dioxide ( $\text{CO}_2$ ) until the working pressure is reached (80-120 bar, preferably 100 bar). The  $\text{CO}_2$  is dispersed in the solution  
5 through the filter. This antisolvent, which is first gaseous and then supercritical, can be mixed perfectly with the liquid solvent (DMSO) but it is a nonsolvent for the polymer.

The loading rate, or the pressure gradient over time, is set in a range of 3-20 bar/min, preferably 10 bar/min. The temperature in the  
10 precipitator is kept constant in a range of between 25°C and 60°C, preferably 40 °C.

When the working pressure has been reached, the flow of  $\text{CO}_2$  is switched off for 10 minutes to obtain the desired pressure and temperature conditions inside the precipitator. The washing operation  
15 is begun by supplying antisolvent to the precipitator and regulating the outlet flow from the top of the precipitator by means of a millimetric valve.

The outlet fluid, constituted by antisolvent and DMSO, is directed towards the DMSO collector, which is kept at room pressure; the DMSO  
20 separates after expansion and consequent cooling, while the gaseous  $\text{CO}_2$  comes out of the top of the container and is released into the atmosphere. The solid particles, on the other hand, are trapped by the porous filters at the top and base of the precipitator.

The operation is continued to allow the DMSO to be completely removed  
25 from the precipitator. The time it takes for the organic solvent to be removed by the supercritical antisolvent depends on the temperature in the precipitation chamber, when fixed amount of liquid solution an

- 15 -

antisolvent flow rate are set up.

At the end of washing, the supply of CO<sub>2</sub> is cut off and the container is depressurized at a rate of 5 bar/min. The container is opened, the microspheres are collected and placed in suitable containers where 5 they are stored at 4°C. The yield of microspheres is almost total.

There is no appreciable incorporation of solvent in the precipitate. The DMSO is collected in the expansion container.

The mean particle size in these working conditions is 0.6 μ (Fig. 12).

10 Example 2: Preparation of microspheres wherein the starting polymer is HYAFF-11 p75 (partial benzyl ester of hyaluronic acid)

A hyaluronic acid ester, wherein 75% of the carboxy groups of hyaluronic acid are esterified with benzyl alcohol, while the remaining part is salified with sodium, is dissolved in an aprotic 15 solvent such as dimethylsulfoxide (DMSO), at a concentration varying between 0.1 and 5% in weight, generally 1% w/w. Once the polymer has reached solubilization, the solution is poured into a pressure-proof container (precipitator), thermostatically controlled by a heated ethylene glycol jacket. Porous steel filters with a cut-off of 0.1 20 μ are screwed onto the top and base of the precipitator. The liquid is unable to seep through by gravity alone.

Once the vessel is closed, it is loaded from underneath with hyperpure carbon dioxide (CO<sub>2</sub>) until the working pressure is reached (80-120 bar, preferably 100 bar). The CO<sub>2</sub> is distributed in the solution 25 through the porous filter. This antisolvent, which is first gaseous and then supercritical, can be mixed perfectly with the liquid solvent (DMSO) but it is a nonsolvent for the polymer.

- 16 -

The loading rate, or the pressure gradient over time, is set in a range of 3-20 bar/min, preferably 10 bar/min. The temperature in the precipitator is kept constant in a range of between 25°C and 60°C, preferably 40°C.

5 When the working pressure has been reached, the flow of CO<sub>2</sub> is switched off for 10 minutes to obtain the desired pressure and temperature conditions inside the precipitator. The washing operation is begun by supplying antisolvent to the precipitator and regulating the outlet flow from the top of the precipitator by means of a  
10 millimetric valve.

The outlet fluid, constituted by antisolvent and DMSO, is directed towards the DMSO collector, which is kept at room pressure; the DMSO separates after expansion and consequent cooling, while the gaseous CO<sub>2</sub> comes out of the top of the vessel and is dispersed in the  
15 atmosphere. The solid particles, on the other hand, are trapped by the porous filters at the top and bottom of the precipitator.

The operation is continued to allow the DMSO to be completely removed from the precipitator. The time it takes for the organic solvent to be removed by the supercritical antisolvent depends on the temperature in  
20 the precipitation chamber, when fixed amount of liquid solution and antisolvent flow rate are set up.

At the end of washing, the supply of CO<sub>2</sub> is cut off and the vessel is depressurized at a rate of 5 bar/min. The vessel is opened, the microspheres are collected and placed in suitable containers where  
25 they are stored at 4°C. The yield of microspheres is almost total. There is no appreciable incorporation of solvent in the precipitate. The DMSO is collected in the expansion container.

- 17 -

The mean particle size in these working conditions is 0.8  $\mu$  (Fig. 3).

Example 3: Preparation of microspheres wherein the starting polymer is HYAFF-7 (ethyl ester of hyaluronic acid)

5 A hyaluronic acid ester, wherein all the carboxy groups of hyaluronic acid are esterified with ethyl alcohol, is dissolved in an aprotic solvent such as dimethylsulfoxide (DMSO), at a concentration varying between 0.1 and 5% in weight, generally 1% w/w. Once the polymer has reached solubilization, the solution is poured into a pressure-proof 10 vessel (precipitator), thermostatically controlled by a heated ethylene glycol jacket. Porous steel filters with a cut-off of 0.1  $\mu$  are screwed onto the top and bottom of the precipitator. The liquid is unable to seep through by gravity alone.

Once the vessel is closed, it is loaded from underneath with hyperpure 15 carbon dioxide ( $\text{CO}_2$ ) until the working pressure is reached (80-120 bar, preferably 100 bar). The  $\text{CO}_2$  is distributed in the solution through the porous base. This antisolvent, which is first gaseous and then supercritical, can be mixed perfectly with the liquid solvent (DMSO) but it is a nonsolvent for the polymer.

20 The loading rate, or the pressure gradient over time, is set in a range of 3-20 bar/min, preferably 10 bar/min. The temperature in the precipitator is kept constant in a range of between 25°C and 60°C, preferably 40°C.

When the working pressure has been reached, the flow of  $\text{CO}_2$  is 25 switched off for 10 minutes to obtain the desired pressure and temperature conditions inside the precipitator. The washing operation is begun by supplying antisolvent to the precipitator and regulating

- 18 -

the outlet flow from the top of the precipitator by means of a millimetric valve.

The outlet fluid, constituted by antisolvent and DMSO, is directed towards the DMSO collector, which is kept at room pressure; the DMSO 5 separates after expansion and consequent cooling, while the gaseous CO<sub>2</sub> comes out of the top of the vessel and is released into the atmosphere. The solid particles, on the other hand, are trapped by the porous filters at the top and base of the precipitator.

The operation is continued to allow the DMSO to be completely removed 10 from the precipitator. The time it takes for the organic solvent to be removed by the supercritical antisolvent depends on the temperature in the precipitation chamber, when fixed amount of liquid solution and antisolvent flow rate are set up.

At the end of washing, the supply of CO<sub>2</sub> is cut off and the vessel is 15 depressurized at a rate of 5 bar/min. The vessel is opened, the microspheres are collected and placed in suitable containers where they are stored at 4°C. The yield of microspheres is almost total.

There is no appreciable incorporation of solvent in the precipitate.

The DMSO is collected in the expansion container.

20 The mean particle size in these working conditions is 1.0 μ (Fig. 4).

Example 4: Preparation of microspheres wherein the starting polymer is a crosslinked polysaccharide of hyaluronic acid (ACP)

A hyaluronic acid derivative, wherein 10% of the carboxy groups of 25 hyaluronic acid are bound with inter- or intramolecular hydroxy groups and the remaining part is salified with sodium, is dissolved in an aprotic solvent such as dimethylsulfoxide (DMSO), at a concentration

- 19 -

varying between 0.1 and 5% in weight, generally 1% w/w. The procedure described in Example 1 is then performed. The mean particle size is 0.6  $\mu$  (Fig. 5).

Example 5: Preparation of microspheres wherein the starting polymer is

5 an ester of alginic acid (ALAFF)

A derivative of alginic acid, wherein all the carboxy groups of alginic acid are esterified with benzyl alcohol, is dissolved in an aprotic solvent, such as dimethylsulfoxide (DMSO), at a concentration varying between 0.1 and 5% in weight, generally 1% w/w. The procedure described in Example 1 is then performed. The mean particle size is 10 0.8  $\mu$  (Fig. 6).

Example 6: Preparation of microspheres wherein the starting polymer is

an ester of pectinic acid

A derivative of pectinic acid, wherein all the carboxy groups are esterified with benzyl alcohol, is dissolved in an aprotic solvent, 15 such as dimethylsulfoxide (DMSO), at a concentration varying between 0.1 and 5% in weight, generally 1% w/w. The procedure described in Example 1 is then performed.

The mean particle size is 0.7  $\mu$ .

20 Example 7: Preparation of microspheres wherein the starting polymer is HYAFF-11 (benzyl ester of hyaluronic acid) and which are loaded with calcitonin

A hyaluronic acid ester, wherein all the carboxy groups of hyaluronic acid are esterified with benzyl alcohol, is dissolved in an aprotic 25 solvent such as dimethylsulfoxide (DMSO), at a concentration varying between 0.1% and 5% in weight, generally 1% w/w. Once the polymer has reached solubilization, the calcitonin is added to the polymeric

- 20 -

solution at the set concentration, eg 1.5 I.U. per mg of polymer.

The solution thus obtained is poured into a pressure-proof vessel (precipitator), thermostatically controlled by a heated ethylene glycol jacket. Porous steel filters with a cut-off of 0.1  $\mu$  are

5 screwed onto the top and base of the precipitator. The liquid is unable to seep through by gravity alone.

Once the vessel is closed, it is loaded from underneath with hyperpure carbon dioxide ( $\text{CO}_2$ ) until the working pressure is reached (80-120 bar, preferably 100 bar). The  $\text{CO}_2$  is distributed in the solution  
10 through the porous base. This antisolvent, which is first gaseous and then supercritical, can be mixed perfectly with the liquid solvent (DMSO) but it is a nonsolvent for the polymer and the polypeptide calcitonin.

The loading rate, or the pressure gradient over time, is set in a  
15 range of 3-20 bar/min, preferably 10 bar/min. The temperature in the precipitator is kept constant in a range of between 25°C and 60°C, preferably 40°C.

When the working pressure has been reached, the flow of  $\text{CO}_2$  is switched off for 10 minutes to obtain the desired pressure and  
20 temperature conditions inside the precipitator. The washing operation is begun by supplying antisolvent to the precipitator and regulating the outlet flow from the top of the precipitator by means of a millimetric valve.

The outlet fluid, constituted by antisolvent and DMSO, is directed  
25 towards the DMSO collector, which is kept at room pressure; the DMSO separates after expansion and consequent cooling, while the gaseous  $\text{CO}_2$  comes out of the top of the vessel and is released into the

- 21 -

atmosphere. The solid particles, on the other hand, are trapped by the porous filters at the top and base of the precipitator.

The operation is continued to allow the DMSO to be completely removed from the precipitator. The time it takes for the organic solvent to be  
5 removed by the supercritical antisolvent depends on the temperature in the precipitation chamber, when fixed amount of liquid solution and antisolvent flow rate are set up.

At the end of washing, the supply of CO<sub>2</sub> is cut off and the vessel is depressurized at a rate of 5 bar/min. The vessel is opened, the  
10 microspheres are collected and placed in suitable containers where they are stored at 4°C. The yield of microspheres is almost total. There is no appreciable incorporation of solvent in the precipitate. The DMSO is collected in the expansion container.

The mean particle size in these working conditions is 0.5 μ. The  
15 quantity of incorporated calcitonin is 1.3 I.U. per mg of microspheres.

Example 8: Preparation of microspheres wherein the starting polymer is HYAFF-11 p75 (benzyl ester of hyaluronic acid) and which are loaded with calcitonin

20 A hyaluronic acid ester, wherein 75% of the carboxy groups of hyaluronic acid are esterified with benzyl alcohol, while the remaining part is salified with sodium, is dissolved in an aprotic solvent such as dimethylsulfoxide (DMSO), at a concentration varying between 0.1 and 5% in weight, generally 1% w/w. Once the polymer has  
25 reached solubilization, calcitonin is added to the polymeric solution at a set concentration, eg 1.0 I.U. per mg of polymer.

The solution thus obtained is poured into a pressure-proof vessel

- 22 -

(precipitator), thermostatically controlled by a heated ethylene glycol jacket. Porous steel filters with a cut-off of 0.1  $\mu$  are screwed onto the top and base of the precipitator. The liquid is unable to seep through by gravity alone.

5 Once the vessel is closed, it is loaded from underneath with hyperpure carbon dioxide ( $\text{CO}_2$ ) until the working pressure is reached (80-120 bar, preferably 100 bar). The  $\text{CO}_2$  is distributed in the solution through the porous filter. This antisolvent, which is first gaseous and then supercritical, can be mixed perfectly with the liquid solvent  
10 (DMSO) but it is a nonsolvent for the polymer and the polypeptide calcitonin.

The loading rate, or the pressure gradient over time, is set in a range of 3-20 bar/min, preferably 10 bar/min. The temperature in the precipitator is kept constant in a range of between 25°C and 60°C,  
15 preferably 40°C.

When the working pressure has been reached, the flow of  $\text{CO}_2$  is switched off for 10 minutes to obtain the desired pressure and temperature conditions inside the precipitator. The washing operation is begun by supplying antisolvent to the precipitator and regulating  
20 the outlet flow from the top of the precipitator by means of a millimetric valve.

The outlet fluid, constituted by antisolvent and DMSO, is directed towards the DMSO collector, which is kept at room pressure; the DMSO separates after expansion and consequent cooling, while the gaseous  
25  $\text{CO}_2$  comes out of the top of the vessel and is released into the atmosphere. The solid particles, on the other hand, are trapped by the porous filters at the top and base of the precipitator.

- 23 -

The operation is continued to allow the DMSO to be completely removed from the precipitator. The time it takes for the organic solvent to be removed by the supercritical antisolvent depends on the temperature in the precipitation chamber, when fixed amount of liquid solution and 5 antisolvent flow rate are set up.

At the end of washing, the supply of CO<sub>2</sub> is cut off and the vessel is depressurized at a rate of 5 bar/min. The vessel is opened, the microspheres are collected and placed in suitable containers where they are stored at 4°C. The yield of microspheres is almost total.  
10 There is no appreciable incorporation of solvent in the precipitate. The DMSO is collected in the expansion container.

The mean particle size in these working conditions is 0.8 μ. The quantity of incorporated calcitonin is 0.9 I.U. per mg of microspheres.  
15 Example 9: Preparation of microspheres wherein the starting polymer is HYAFF-7 (ethyl ester) of hyaluronic acid, and which are loaded with calcitonin

A hyaluronic acid ester, wherein all the carboxy groups of hyaluronic acid are esterified with ethyl alcohol, is dissolved in an aprotic 20 solvent such as dimethylsulfoxide (DMSO), at a concentration varying between 0.1 and 5% in weight, generally 1% w/w. Once the polymer has reached solubilization, calcitonin is added to the polymeric solution at a set concentration, eg 15 I.U. per mg of polymer.

The solution thus obtained is poured into a pressure-proof vessel 25 (precipitator), thermostatically controlled by a heated ethylene glycol jacket. Porous steel filters with a cut-off of 0.1 μ are screwed onto the top and base of the precipitator. The liquid is

- 24 -

unable to seep through by gravity alone.

Once the vessel is closed, it is loaded from underneath with hyperpure carbon dioxide ( $\text{CO}_2$ ) until the working pressure is reached (80-120 bar, preferably 100 bar). The  $\text{CO}_2$  is distributed in the solution  
5 through the porous base. This antisolvent, which is first gaseous and then supercritical, can be mixed perfectly with the liquid solvent (DMSO) but it is a nonsolvent for the polymer and the polypeptide calcitonin.

The loading rate, or the pressure gradient over time, is set in a  
10 range of 3-20 bar/min, preferably 10 bar/min. The temperature in the precipitator is kept constant in a range of between 25°C and 60°C, preferably 40°C.

When the working pressure has been reached, the flow of  $\text{CO}_2$  is switched off for 10 minutes to obtain the desired pressure and  
15 temperature conditions inside the precipitator. The washing operation is begun by supplying antisolvent to the precipitator and regulating the outlet flow from the top of the precipitator by means of a millimetric valve.

The outlet fluid, constituted by antisolvent and DMSO, is directed  
20 towards the DMSO collector, which is kept at room pressure; the DMSO separates after expansion and consequent cooling, while the gaseous  $\text{CO}_2$  comes out of the top of the vessel and is released into the atmosphere. The solid particles, on the other hand, are trapped by the porous filters at the top and bottom of the precipitator.

25 The operation is continued to allow the DMSO to be completely removed from the precipitator. The time it takes for the organic solvent to be removed by the supercritical antisolvent depends on the temperature in

- 25 -

the precipitation chamber, when fixed amount of liquid solution and antisolvent flow rate are set up.

At the end of washing, the supply of CO<sub>2</sub> is cut off and the vessel is depressurized at a rate of 5 bar/min. The vessel is opened. the  
5 microspheres are collected and placed in suitable containers where they are stored at 4°C. The yield of microspheres is almost total. There is no appreciable incorporation of solvent in the precipitate. The DMSO is collected in the expansion container.

The mean particle size in these working conditions is 1.0 μ. The  
10 quantity of incorporated calcitonin is 13 I.U. per mg of microspheres.

Example 10: Preparation of microspheres wherein the starting polymer is HYAFF-11 (benzyl ester of hyaluronic acid), and which contain GMCSF (granulocyte macrophage colony stimulating factor).

A hyaluronic acid ester, wherein all the carboxy groups of hyaluronic  
15 acid are esterified with benzyl alcohol, is dissolved in an aprotic solvent such as dimethylsulfoxide (DMSO), at a concentration which varies between 0.1 and 5% in weight, generally 1% w/w. Once the polymer has reached solubilization, GMCSF is added to the polymer solution at a set concentration, eg 1% of the polymer mass.

20 The solution thus obtained is poured into a pressure-proof vessel (precipitator), thermostatically controlled by a heated ethylene glycol jacket. Porous steel filters with a cut-off of 0.1 μ are screwed onto the top and base of the precipitator. The liquid is unable to seep through by gravity alone.

25 Once the vessel is closed, it is loaded from underneath with hyperpure carbon dioxide (CO<sub>2</sub>) until the working pressure is reached (80-120 bar, preferably 100 bar). The CO<sub>2</sub> is distributed in the solution

- 26 -

through the porous base. This antisolvent, which is first gaseous and then supercritical, can be mixed perfectly with the liquid solvent (DMSO) but it is a nonsolvent for the polymer and the polypeptide GMCSF.

5 The loading rate, or the pressure gradient over time, is set in a range of 3-20 bar/min, preferably 10 bar/min. The temperature in the precipitator is kept constant in a range of between 25°C and 60°C, preferably 40°C.

When the working pressure has been reached, the flow of CO<sub>2</sub> is  
10 switched off for 10 minutes to obtain the desired pressure and temperature conditions inside the precipitator. The washing operation is begun by supplying antisolvent to the precipitator and regulating the outlet flow from the top of the precipitator by means of a millimetric valve.

15 The outlet fluid, constituted by antisolvent and DMSO, is directed towards the DMSO collector, which is kept at room pressure; the DMSO separates after expansion and consequent cooling, while the gaseous CO<sub>2</sub> comes out of the top of the vessel and is released into the atmosphere. The solid particles, on the other hand, are trapped by the  
20 porous filters at the top and base of the precipitator.

The operation is continued to allow the DMSO to be completely removed from the precipitator. The time it takes for the organic solvent to be removed by the supercritical antisolvent depends on the temperature in the precipitation chamber, when fixed amount of liquid and antisolvent  
25 flow rate are set up.

At the end of washing, the supply of CO<sub>2</sub> is cut off and the vessel is depressurized at a rate of 5 bar/min. The vessel is opened, the

- 27 -

microspheres are collected and placed in suitable containers where they are stored at 4°C. The yield of microspheres is almost total. There is no appreciable incorporation of solvent in the precipitate. The DMSO is collected in the expansion container.

5 The mean particle size in these working conditions is 0.5 μ. The quantity of incorporated GMCSF is 9 μg. per mg of microspheres.

Example 11: Preparation of microspheres wherein the starting polymer is HYAFF-11 p75 (benzyl ester of hyaluronic acid), and which contain GMCSF (granulocyte macrophage colony stimulating factor)

A hyaluronic acid ester, wherein 75% of the carboxy groups of hyaluronic acid are esterified with benzyl alcohol while the remaining part is salified with sodium, is dissolved in an aprotic solvent such as dimethylsulfoxide (DMSO), at a concentration varying between 0.1 and 5% in weight, generally 1% w/w. Once the polymer has reached solubilization, GMCSF is added to the polymeric solution at a set concentration, eg 2% of the polymer mass.

The solution thus obtained is poured into a pressure-proof vessel (precipitator), thermostatically controlled by a heated ethylene glycol jacket. Porous steel filters with a cut-off of 0.1 μ are screwed onto the top and base of the precipitator. The liquid is unable to seep through by gravity alone.

Once the vessel is closed, it is loaded from underneath with hyperpure carbon dioxide (CO<sub>2</sub>) until the working pressure is reached (80-120 bar, preferably 100 bar). The CO<sub>2</sub> is distributed in the solution through the porous base. This antisolvent, which is first gaseous and then supercritical, can be mixed perfectly with the liquid solvent

- 28 -

(DMSO) but it is a nonsolvent for the polymer and the polypeptide GMCSF.

The loading rate, or the pressure gradient over time, is set in a range of 3-20 bar/min, preferably 10 bar/min. The temperature in the 5 precipitator is kept constant in a range of between 25°C and 60°C, preferably 40°C.

When the working pressure has been reached, the flow of CO<sub>2</sub> is switched off for 10 minutes to obtain the desired pressure and 10 temperature conditions inside the precipitator. The washing operation is begun by supplying antisolvent to the precipitator and regulating the outlet flow from the top of the precipitator by means of a millimetric valve.

The outlet fluid, constituted by antisolvent and DMSO, is directed towards the DMSO collector, which is kept at room pressure; the DMSO 15 separates after expansion and consequent cooling, while the gaseous CO<sub>2</sub> comes out of the top of the vessel and is released into the atmosphere. The solid particles, on the other hand, are trapped by the porous filters at the top and base of the precipitator.

The operation is continued to allow the DMSO to be completely removed 20 from the precipitator. The time it takes for the organic solvent to be removed by the supercritical antisolvent depends on the temperature in the precipitation chamber, when fixed amount of liquid solution and antisolvent flow rate are set up.

At the end of washing, the supply of CO<sub>2</sub> is cut off and the vessel is 25 depressurized at a rate of 5 bar/min. The vessel is opened, the microspheres are collected and placed in suitable containers where they are stored at 4°C. The yield of microspheres is almost total.

- 29 -

There is no appreciable incorporation of solvent in the precipitate.

The DMSO is collected in the expansion container.

The mean particle size in these working conditions is 0.8  $\mu$ . The quantity of incorporated GMCSF is 17  $\mu$ g per mg of microspheres.

5     Example 12: Preparation of microspheres wherein the starting polymer is HYAFF-7 (ethyl ester of hyaluronic acid), and which are loaded with GMCSF (granulocyte macrophage colony stimulating factor)

10    A hyaluronic acid ester, wherein all the carboxy groups of hyaluronic acid are esterified with ethyl alcohol, is dissolved in an aprotic solvent such as dimethylsulfoxide (DMSO), at a concentration varying between 0.1 and 5% in weight, generally 1% w/w. Once the polymer has reached solubilization, GMCSF is added to the polymeric solution at a set concentration, eg 0.1% of the polymer mass.

15    The solution thus obtained is poured into a pressure-proof vessel (precipitator), thermostatically controlled by a heated ethylene glycol jacket. Porous steel filters with a cut-off of 0.1  $\mu$  are screwed onto the top and base of the precipitator. The liquid is unable to seep through by gravity alone.

20    Once the vessel is closed, it is loaded from underneath with hyperpure carbon dioxide ( $CO_2$ ) until the working pressure is reached (80-120 bar, generally 100 bar). The  $CO_2$  is distributed in the solution through the porous base. This antisolvent, which is first gaseous and then supercritical, can be mixed perfectly with the liquid solvent (DMSO) but it is a nonsolvent for the polymer and the polypeptide GMCSF.

The loading rate, or the pressure gradient over time, is set in a

- 30 -

range of 3-20 bar/min, preferably 10 bar/min. The temperature in the precipitator is kept constant in a range of between 25°C and 60°C, preferably 40°C.

When the working pressure has been reached, the flow of CO<sub>2</sub> is  
5 switched off for 10 minutes to obtain the desired pressure and temperature conditions inside the precipitator. The washing operation is begun by supplying antisolvent to the precipitator and regulating the outlet flow from the top of the precipitator by means of a millimetric valve.

10 The outlet fluid, constituted by antisolvent and DMSO, is directed towards the DMSO collector, which is kept at room pressure; the DMSO separates after expansion and consequent cooling, while the gaseous CO<sub>2</sub> comes out of the top of the vessel and is released into the atmosphere. The solid particles, on the other hand, are trapped by the  
15 porous filters at the top and bottom of the precipitator.

The operation is continued to allow the DMSO to be completely removed from the precipitator. The time it takes for the organic solvent to be removed by the supercritical antisolvent depends on the temperature in the precipitation chamber, when fixed amount of liquid solution and  
20 antisolvent flow rate are set up.

At the end of washing, the supply of CO<sub>2</sub> is cut off and the vessel is depressurized at a rate of 5 bar/min. The vessel is opened, the microspheres are collected and placed in suitable containers where they are stored at 4°C. The yield of microspheres is almost total.  
25 There is no appreciable incorporation of solvent in the precipitate.

The DMSO is collected in the expansion container.

The mean particle size in these working conditions is 1.0 μ. The

- 31 -

quantity of incorporated GMCSF is 0.9 µg per mg of microspheres.

Example 13: Preparation of microspheres wherein the starting polymer is HYAFF-11 (benzyl ester of hyaluronic acid), and which are loaded with human insulin

5 A hyaluronic acid ester, wherein all the carboxy groups of hyaluronic acid are esterified with benzyl alcohol, is dissolved in an aprotic solvent such as dimethylsulfoxide (DMSO), at a concentration varying between 0.1 and 5% in weight, generally 1% w/w. Once the polymer has reached solubilization, human insulin is added to the polymeric solution at a set concentration, eg 5 I.U. per mg of polymer.

10 The solution thus obtained is poured into a pressure-proof vessel (precipitator), thermostatically controlled by a heated ethylene glycol jacket. Porous steel filters with a cut-off of 0.1 µ are screwed onto the top and base of the precipitator. The liquid is 15 unable to seep through by gravity alone.

Once the vessel is closed, it is loaded from underneath with hyperpure carbon dioxide (CO<sub>2</sub>) until the working pressure is reached (80-120 bar, preferably 100 bar). The CO<sub>2</sub> is distributed in the solution through the porous base. This antisolvent, which is first gaseous and 20 then supercritical, can be mixed perfectly with the liquid solvent (DMSO) but it is a nonsolvent for the polymer and the polypeptide human insulin.

The loading rate, or the pressure gradient over time, is set in a range of 3-20 bar/min, preferably 10 bar/min. The temperature in the 25 precipitator is kept constant in a range of between 25°C and 60°C, preferably 40°C.

When the working pressure has been reached, the flow of CO<sub>2</sub> is

- 32 -

switched off for 10 minutes to obtain the desired pressure and temperature conditions inside the precipitator. The washing operation is begun by supplying antisolvent to the precipitator and regulating the outlet flow from the top of the precipitator by means of a millimetric valve.

The outlet fluid, constituted by antisolvent and DMSO, is directed towards the DMSO collector, which is kept at room pressure; the DMSO separates after expansion and consequent cooling, while the gaseous CO<sub>2</sub> comes out of the top of the vessel and is released into the atmosphere. The solid particles, on the other hand, are trapped by the porous filters at the top and bottom of the precipitator.

The operation is continued to allow the DMSO to be completely removed from the precipitator. The time it takes for the organic solvent to be removed by the supercritical antisolvent depends on the temperature in the precipitation chamber, when fixed amount of liquid solution and antisolvent flow rate are set up.

At the end of washing, the supply of CO<sub>2</sub> is cut off and the vessel is depressurized at a rate of 5 bar/min. The vessel is opened, the microspheres are collected and placed in suitable containers where they are stored at 4°C. The yield of microspheres is almost total. There is no appreciable incorporation of solvent in the precipitate.

The DMSO is collected in the expansion container.

The mean particle size in these working conditions is 0.8 μ. The quantity of incorporated insulin is 5 I.U. per mg of microspheres.

Example 14: Surface loading of microspheres of HYAFF-11 (benzyl ester of hyaluronic acid) with calcitonin by lyophilization

Microspheres prepared according to Example 1 are suspended in a

- 33 -

solution of 0.01M phosphate buffer, containing calcitonin in a concentration which gives a protein titer of 1 I.U. per mg of suspended microspheres. After 15 minutes' shaking with a semiautomatic device, the container is immersed in liquid nitrogen until the 5 suspension is completely frozen.

Once frozen, the container is lyophilized for 24 hours, after which the lyophilized product is stored at 4°C.

The mean particle size in these working conditions is 0.4  $\mu$ . The quantity of incorporated calcitonin is 1 I.U. per mg of microspheres.

10 Example 15: Surface loading of microspheres of HYAFF-11 p75 (benzyl ester of hyaluronic acid) with calcitonin by lyophilization

Microspheres prepared according to Example 2 are suspended in a solution of 0.01M phosphate buffer, containing calcitonin in a concentration which gives a protein titer of 1.5 I.U. per mg of 15 suspended microspheres. After 15 minutes' stirring with a semiautomatic device, the container is immersed in liquid nitrogen until the suspension is completely frozen.

Once frozen, the container is lyophilized for 24 hours, after which the lyophilized product is stored at 4°C.

20 The mean particle size in these working conditions is 0.6  $\mu$ . The quantity of incorporated calcitonin is 1.5 I.U. per mg of microspheres.

**CLAIMS**

1. Microspheres having a diameter  $\geq$  0,1 and  $<$  1  $\mu$  comprising a biocompatible polysaccharide polymer.
2. The microspheres according to claim 1 wherein said biocompatible polysaccharide polymer is an ester of an acidic polysaccharide selected from the group consisting of hyaluronic acid esters, crosslinked esters of hyaluronic acid, esters of chitin, esters of pectin, the esters of gellan, the esters of alginic acid.
3. The microspheres according to claim 2 wherein said esters are the ethyl or benzyl ester of said acidic polysaccharide.
4. The microspheres according to one of claims 1-3 comprising the partial or total benzyl ester of hyaluronic acid.
5. The microspheres according to one of claims 1-4 further comprising at least one active principle selected from the group consisting of: a pharmaceutically active polypeptide, a Granulocyte Macrophage Colony Stimulating Factor (GMCSF), a trophic factor, an immunoglobulin, a natural or a synthetic derivative of a ganglioside, an antiviral, an antiasthmatic, an antiinflammatory agent, an antibiotic and an antimycotic agent.
6. The microspheres according to claim 5 wherein said pharmaceutically active polypeptide is selected from the group consisting of calcitonin, insulin.
7. The microspheres according to claim 5 wherein said trophic factor, is selected from the group consisting of: Nerve Growth Factor (h-NGF), Ciliary Neuronotrophic Growth Factor (h-CNTF).
8. The microspheres according to one of claims 1-4, consisting of said biocompatible polysaccharide polymer.

1    9. Pharmaceutical compositions administrable by oral, nasal,  
2    pulmonary, vaginal or rectal route, containing the microspheres  
3    according to one of claims 1-4 and 8 as vehicling agents or carriers,  
4    in combination with at least one active principle and optionally  
5    other conventional excipients.

1    10. Pharmaceutical compositions administrable by oral, nasal,  
2    pulmonary, vaginal or rectal route, containing the microspheres  
3    according to one of claims 5-7 optionally in combination with other  
4    excipients.

1    11. The pharmaceutical compositions according to one of claims 9 and  
2    10 in a controlled release form, further containing suitable  
3    excipients normally used for preparing controlled release  
4    pharmaceutical compositions.

1    12. Use of microspheres having a diameter of between 0.1 and 1  $\mu$  and  
2    comprising a biocompatible polysaccharide polymer as a tracer  
3    carrier in the diagnostic field.

1    13. The use according to claim 12 wherein said biocompatible  
2    polysaccharide polymer is an ester of an acidic polysaccharide,  
3    selected from the group consisting of hyaluronic acid esters,  
4    crosslinked esters of hyaluronic acid, esters of chitin, esters of  
5    pectin, esters of gellan, esters of alginic acid.

1    14. The use according to one of claims 12, 13 wherein said esters are  
2    the ethyl or benzyl ester of said acidic polysaccharide .

1    15. The use according to one of claims 12-14 wherein the microspheres  
2    comprise the partial or total benzyl ester of hyaluronic acid .

1    16. Use of microspheres having a diameter of between 0.1 and 1  $\mu$  and  
2    containing a biocompatible polysaccharide polymer, as a carrier in

3 the agro-alimentary industry.

1 17. The use according to claim 16 wherein said biocompatible  
2 polysaccharide polymer is an ester of an acidic polysaccharide  
3 selected from the group consisting of hyaluronic acid esters,  
4 crosslinked esters of hyaluronic acid, esters of chitin, esters of  
5 pectin, esters of gellan, esters of alginic acid.

1 18. The use according to one of claims 16.17 wherein said esters are  
2 the ethyl or benzyl ester of said acidic polysaccharide .

1 19. The use according to one of claims 16-18 wherein the microspheres  
2 comprise in the partial ester or total benzyl ester of hyaluronic acid.

1 20. Use of microspheres having of between 0.1 and 1  $\mu$  and comprising  
2 a biocompatible polysaccharide polymer, as carriers or vehicles of  
3 single genes in the preparation of pharmaceutical compositions for the  
4 treatment of diseases associated with genic defects.

1 21. The use according to claim 20 wherein said diseases are the  
2 consequence of a deficit or hyperactivity of an enzyme, caused by  
3 defects in the gene encoding said enzyme.

1 22. The use according to claim 20 wherein said diseases are  
2 malformative diseases of genetic origin and hereditary diseases.

1 23. The use according to one of claims 20-22 wherein said  
2 biocompatible polysaccharide polymer is an ester of an acidic  
3 polysaccharide selected from the group consisting of hyaluronic acid  
4 esters, crosslinked esters of hyaluronic acid, esters of chitin,  
5 esters of pectin, esters of gellan, esters of alginic acid.

1 24. The use according to one of claims 20-23 wherein said esters are  
2 the ethyl or benzyl ester of said acidic polysaccharide .

1 25. The use according to one of claims 20-24 wherein the microspheres

- 37 -

2 comprise the partial or total benzyl ester of hyaluronic acid.

1 26. A discontinuous process for the preparation of microspheres  
2 having a diameter of between 0.1 and 1  $\mu$  and comprising a  
3 biocompatible polysaccharide, said process comprising the following  
4 steps:

5 a) dissolving the polysaccharide biocompatible polymer in an aprotic  
6 solvent at concentrations ranging from 0.1 to 5% by weight,

7 b) charging the solution of step (a) in a pressure proof container  
8 having at the top and at the base steel filters with an average cut-  
9 off lower than 0.1  $\mu$ ;

10 c) loading the antisolvent from underneath until the pressure at  
11 which the fluid becomes supercritical at a temperature ranging from  
12 25° to 60°C is reached.

13 d) removing the aprotic solvent with a flow of said supercritical  
14 fluid,

15 e) depressurizing the pressure proof container, and collecting the  
16 precipitated product.

1 27. The process according to claim 26 wherein the fluid to be used  
2 under supercritical condition is selected from the group consisting  
3 of carbon dioxide, hydrofluorocarbons.

1 28. The process according to claim 27 wherein CO<sub>2</sub> is charged at a  
2 loading rate or pressure gradient ranging from 3 to 20 bar/min. until  
3 a pressure from 80 to 120 bar/min is reached in the pressure proof  
4 container.

1 29. The process according to one of claims 26-28 wherein said aprotic  
2 solvent used in step (a) to dissolve the biocompatible polysaccharide  
3 polymer is selected from dimethylsulfoxide and N-methylpyrrolidone.

1       30. The process according to one of claims 26-29 wherein said  
2       biocompatible polysaccharide polymer contained in the microspheres is  
3       an ester of an acidic polysaccharide selected from the group  
4       consisting of hyaluronic acid esters, crosslinked esters of hyaluronic  
5       acid, esters of chitin, esters of pectin, the esters of gellan, the  
6       esters of alginic acid.

1       31. The process according to one of claims 26-30 wherein said ester  
2       is the ethyl or benzyl ester of said acidic polysaccharide.

1       32. The process according to one of claims 26-31 for preparing  
2       microspheres comprising the partial ester or total benzyl ester of  
3       hyaluronic acid.

1       33. The process according to one of claims 26-29 for preparing the  
2       microspheres according to claims 5-7 wherein the active principle is  
3       added in step (a), after the dissolution of the biocompatible  
4       polysaccharide polymer in the aprotic solvent.

1       34. The process according to one of claims 26-29 for preparing the  
2       microspheres according to claims 5-7 wherein the microspheres from  
3       step (e), are suspended in a buffered solution containing the desired  
4       active principle at a suitable concentration in order to obtain the  
5       desired active ingredient titer/mg of microsphere, and the suspension  
6       is subjected to liophylization at the liquid nitrogen temperature.

- 39 -

MICROSPHERES COMPRISING A BIOCOMPATIBLE POLYSACCHARIDE POLYMER, A PROCESS FOR THEIR PREPARATION, AND THEIR USE AS VEHICLING AGENT IN THE PHARMACEUTICAL, DIAGNOSTIC AND AGROALIMENTARY INDUSTRY FIELD.

ABSTRACT

5    Microspheres, having a size lower than 1  $\mu$  and comprising a biocompatible polysaccharidic polymer, are prepared with a process comprising the precipitation of polymer induced by means of a supercritical antisolvent (SAS). These microspheres are used as vehicling agents or carriers in the preparation of pharmaceutical  
10   compositions administrable by oral, nasal, pulmonary, vaginal or rectal route. These microspheres can also be advantageously used as vehicling agent or carriers in the preparation of pharmaceutical compositions for the treatment of human diseases associated with genic defects, for the preparation of diagnostics and in the agro-alimentary  
15   industry.

1/3



FIG. 1




FIG. 2

2/3




FIG. 3




FIG. 4




FIG. 5




FIG. 6

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 96/01354

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K9/51

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 82, no. 9, September 1993, WASHINGTON (US), pages 912-917. XP000387588 M. RAJAONARIVONY ET AL.: "DEVELOPMENT OF A NEW DRUG CARRIER MADE FROM ALGINATE" see the whole document ---	1,5-12, 16,20-22
X	FR,A,1 572 106 (BROWN) 27 June 1969 see the whole document ---	1,5-12, 16,20-22
X	US,A,5 129 877 (GALLO ET AL.) 14 July 1992 see the whole document ---	1,5-12, 16,20-22

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- '&' document member of the same patent family

2

Date of the actual completion of the international search

20 August 1996

Date of mailing of the international search report

02.09.96

## Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patendaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax (+31-70) 340-3016

## Authorized officer

Benz, K

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 96/01354

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,93 25195 (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)) 23 December 1993 see the whole document ---	1,5-12, 16,20-22
X	WO,A,83 01738 (SCHRÖDER ET AL.) 26 May 1983 see the whole document	1,5-12, 16,20-22
Y	EP,A,0 517 565 (FIDIA SPA) 9 December 1992 cited in the application  see the whole document ---	3,4, 13-15, 17-19, 23-25
Y	WO,A,90 03782 (THE UPJOHN COMPANY) 19 April 1990 see the whole document -----	3,4, 13-15, 17-19, 23-25
A		26-34

## INTERNATIONAL SEARCH REPORT

Info. section on patent family members

International Application No

PCT/EP 96/01354

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
FR-A-1572106	27-06-69	CH-A-	462383	
		DE-B-	1174014	
		GB-A-	1016606	
		US-A-	3185625	25-05-65
US-A-5129877	14-07-92	NONE		
WO-A-9325195	23-12-93	FR-A-	2692168	17-12-93
		AT-T-	141161	15-08-96
		EP-A-	0646003	05-04-95
		JP-T-	7507784	31-08-95
WO-A-8301738	26-05-83	AU-B-	9127482	01-06-83
		EP-A-	0093757	16-11-83
		US-A-	4501726	26-02-85
		US-A-	4713249	15-12-87
EP-A-517565	09-12-92	IT-B-	1247472	17-12-94
		CA-A-	2070095	01-12-92
		JP-A-	7179363	18-07-95
WO-A-9003782	19-04-90	AU-B-	624421	11-06-92
		AU-B-	4219889	01-05-90
		DE-T-	68907062	07-10-93
		EP-A-	0437451	24-07-91
		HK-A-	89396	31-05-96
		HU-B-	209603	28-09-94
		JP-T-	4500925	20-02-92
		RU-C-	2026670	20-01-95

